Lionel Desroches, MD
Nephrology · Laurelton, NYNPI 1003928987
Payments from drug & device makers
Across 402 payments — averaging $26.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- OPKO Pharmaceuticals, LLC$2K
- AstraZeneca$2K
- Aurinia Pharma U.S., Inc.$835
- Vifor Pharma, Inc.$795
- Travere Therapeutics, Inc.$768
- Amgen$738
- plus $4K from 33 others
What the payments were for
- Food & beverage$10,04393%
- Education$7297%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| OPKO Pharmaceuticals, LLC | 110 | $1,840 |
| AstraZeneca | 52 | $1,596 |
| Aurinia Pharma U.S., Inc. | 12 | $835 |
| Vifor Pharma, Inc. | 20 | $795 |
| Travere Therapeutics, Inc. | 7 | $768 |
| Amgen(2 entities) | 32 | $738 |
| Boehringer Ingelheim | 12 | $592 |
| Merck | 23 | $534 |
| Lilly USA, LLC | 26 | $482 |
| Novo Nordisk | 18 | $464 |
| Otsuka America Pharmaceutical, Inc. | 9 | $236 |
| Bayer | 10 | $221 |
| Akebia Therapeutics Inc | 10 | $194 |
| Pfizer | 10 | $162 |
| Calliditas Therapeutics US Inc. | 1 | $125 |
| Actelion Pharmaceuticals US, Inc. | 1 | $125 |
| Gilead | 1 | $119 |
| Sanofi-aventis U.S. LLC | 6 | $100 |
| Mallinckrodt Hospital Products Inc. | 4 | $98 |
| Fresenius USA Manufacturing, Inc. | 4 | $96 |
| Johnson & Johnson | 4 | $79 |
| Novartis | 4 | $73 |
| AbbVie | 4 | $70 |
| ANI Pharmaceuticals, Inc. | 2 | $50 |
| Amarin Pharma, Inc. | 2 | $41 |
| Sanofi Pasteur Inc. | 2 | $37 |
| GSK | 2 | $35 |
| Fresenius USA Marketing, Inc. | 2 | $34 |
| Mannkind Corporation | 2 | $29 |
| Scpharmaceuticals Inc. | 1 | $29 |
| Daiichi Sankyo Inc. | 1 | $22 |
| Shire North American Group Inc | 1 | $22 |
| Shield Therapeutics Inc | 1 | $21 |
| Bridgebio Pharma, Inc. | 1 | $21 |
| Exact Sciences | 1 | $21 |
| Strongbridge US Inc. | 1 | $20 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $17 |
| Abbott | 1 | $15 |
| Seqirus USA Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,771 in reported general payments places this provider in the 80th percentile of 935 nephrology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 178 | $222,391 |
| MounjaroTirzepatide | 89 | $111,425 |
| JardianceEmpagliflozin | 91 | $105,530 |
| OzempicSemaglutide | 61 | $86,453 |
| RybelsusSemaglutide | 43 | $70,974 |
| JanuviaSitagliptin Phosphate | 78 | $66,631 |
| EliquisApixaban | 57 | $60,527 |
| RayaldeeCalcifediol | 32 | $52,425 |
| JanumetSitagliptin Phos/Metformin Hcl | 40 | $42,404 |
| XareltoRivaroxaban | 22 | $32,479 |
| EntrestoSacubitril/Valsartan | 16 | $26,985 |
| ProsolParenteral Amino Acid 20% No.1 | 116 | $21,950 |
| LokelmaSodium Zirconium Cyclosilicate | 36 | $16,877 |
| LinzessLinaclotide | 23 | $15,754 |
| TradjentaLinagliptin | 15 | $14,816 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma, Symbicort | $1,596 | $242,406225 claims |
| Novo NordiskOzempic, Rybelsus | $464 | $157,427104 claims |
| Lilly USA, LLCMounjaro, Trulicity | $482 | $122,313101 claims |
| Boehringer IngelheimJardiance, Tradjenta | $592 | $120,346106 claims |
| MerckJanuvia, Janumet | $534 | $109,035118 claims |
| PfizerEliquis | $162 | $60,52757 claims |
| OPKO Pharmaceuticals, LLCRayaldee | $1,840 | $52,42532 claims |
| Johnson & JohnsonXarelto, Invokana | $79 | $46,68340 claims |
| NovartisEntresto | $73 | $26,98516 claims |
| AbbVieLinzess | $70 | $15,75423 claims |
| GSKBreo Ellipta | $35 | $13,49330 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 935 nephrology providers in New York.
Other nephrology in Laurelton
- David ScottLaurelton$606K
- Joji TokitaNew York$8.4M
- Krzysztof KirylukNew York$6.7M
- David BernardNew York$6M
- Andrew BombackNew York$3.4M
- Pietro CanettaNew York$3.2M
- Robert LynnBronx$2M
- Jodumutt BhatMaspeth$1.5M
- Gerald AppelNew York$1.5M
- David CharytanNew York$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.